Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease

[1]  J. Molinuevo,et al.  Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy , 2013, Alzheimer's Research & Therapy.

[2]  J. Lindesay,et al.  Donepezil and memantine for moderate-to-severe Alzheimer's disease. , 2012, The New England journal of medicine.

[3]  B. Vellas,et al.  Long-term progression of Alzheimer’s disease in patients under antidementia drugs , 2011, Alzheimer's & Dementia.

[4]  C. Beauchemin,et al.  Economic Evaluation of the Impact of Memantine on Time to Nursing Home Admission in the Treatment of Alzheimer Disease , 2011, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[5]  C. Nyakas,et al.  The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine , 2011, Behavioural Brain Research.

[6]  B. Platt,et al.  The cholinergic system and hippocampal plasticity , 2011, Behavioural Brain Research.

[7]  C. Wattmo,et al.  Predictors of long-term cognitive outcome in Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[8]  George T Grossberg,et al.  Combination Therapy for Alzheimer’s Disease , 2011, Drugs & aging.

[9]  R. Anwyl,et al.  Protection against Aβ-mediated rapid disruption of synaptic plasticity and memory by memantine , 2011, Neurobiology of Aging.

[10]  K. Takata,et al.  Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors* , 2010, The Journal of Biological Chemistry.

[11]  J T O'Brien,et al.  EFNS guidelines for the diagnosis and management of Alzheimer’s disease , 2010, European journal of neurology.

[12]  George T Grossberg,et al.  Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease , 2010, Expert opinion on pharmacotherapy.

[13]  C. Parsons,et al.  Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. , 2010, The American journal of pathology.

[14]  Adam Byron,et al.  Proteomic Analysis of Integrin-Associated Complexes Identifies RCC2 as a Dual Regulator of Rac1 and Arf6 , 2009, Science Signaling.

[15]  F. LaFerla,et al.  Combination of memantine and donepezil reverses cognitive deficits in transgenic mice with both amyloid-beta plaques and neurofibrillary tangles , 2009, Alzheimer's & Dementia.

[16]  C. Parsons,et al.  Memantine reverses ß-amyloid oligomers-induced deficits in long term potentiation (LTP) in murine hippocampal slices , 2009, Alzheimer's & Dementia.

[17]  J. Becker,et al.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[18]  Justin W. Kenney,et al.  Modulation of Hippocampus-Dependent Learning and Synaptic Plasticity by Nicotine , 2008, Molecular Neurobiology.

[19]  A. Atri,et al.  Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease , 2008, Alzheimer disease and associated disorders.

[20]  F. Manes,et al.  P4-405: A multinational, randomized, double-blind, placebo-controlled, parallel-group trial of memantine extended-release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer's disease , 2008, Alzheimer's & Dementia.

[21]  F. Pasquier,et al.  Memantine Therapy for Alzheimer Disease in Real-world Practice: An Observational Study in a Large Representative Sample of French Patients , 2008, Alzheimer disease and associated disorders.

[22]  C. Ballard,et al.  Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. , 2008, The Journal of clinical psychiatry.

[23]  J. Olin,et al.  Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. , 2008, Current Alzheimer research.

[24]  Chris G. Parsons,et al.  Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse , 2007, Neuropharmacology.

[25]  D. Wilkinson,et al.  Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease , 2007, Dementia and Geriatric Cognitive Disorders.

[26]  Hans Förstl,et al.  Memantine (Ebixa®) in Clinical Practice – Results of an Observational Study , 2007, Dementia and Geriatric Cognitive Disorders.

[27]  Roy W Jones,et al.  Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials , 2007, Dementia and Geriatric Cognitive Disorders.

[28]  G. Oster,et al.  Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil* , 2007, Current medical research and opinion.

[29]  W. Klein,et al.  Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.

[30]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[31]  J. Olin,et al.  Cognitive Response to Memantine in Moderate to Severe Alzheimer Disease Patients Already Receiving Donepezil: An Exploratory Reanalysis , 2006, Alzheimer disease and associated disorders.

[32]  J. Olin,et al.  Activities of Daily Living in Moderate-to-Severe Alzheimer Disease: An Analysis of the Treatment Effects of Memantine in Patients Receiving Stable Donepezil Treatment , 2006, Alzheimer disease and associated disorders.

[33]  C. Parsons,et al.  Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. , 2006, Behavioural pharmacology.

[34]  Pierre N Tariot,et al.  Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment , 2006, Neurology.

[35]  J. Olin,et al.  A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[36]  D. Brown,et al.  Simultaneous Release of Glutamate and Acetylcholine from Single Magnocellular “Cholinergic” Basal Forebrain Neurons , 2006, The Journal of Neuroscience.

[37]  M. Sarazin,et al.  Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment , 2005, International journal of clinical practice.

[38]  G. Juhász,et al.  Divergent effects of Aβ1–42 on ionotropic glutamate receptor-mediated responses in CA1 neurons in vivo , 2005, Brain Research.

[39]  S. Gauthier,et al.  Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies , 2005, International journal of geriatric psychiatry.

[40]  Qinying Zhao,et al.  Steady‐State Pharmacokinetics of Galantamine Are Not Affected by Addition of Memantine in Healthy Subjects , 2005, Journal of clinical pharmacology.

[41]  Ramesh C. Gupta,et al.  Memantine does not influence AChE inhibition in rat brain by donepezil or rivastigmine but does with DFP and metrifonate in in vivo studies , 2005 .

[42]  D. Rasmusson,et al.  Cortical acetylcholine release and electroencephalogram activation evoked by ionotropic glutamate receptor agonists in the rat basal forebrain , 2004, Neuroscience.

[43]  A. Enz,et al.  Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain , 2004, Neuropharmacology.

[44]  A. Periclou,et al.  Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil , 2004, The Annals of pharmacotherapy.

[45]  C. Léránth,et al.  Group I metabotropic glutamate receptor activation produces a direct excitation of identified septohippocampal cholinergic neurons. , 2004, Journal of neurophysiology.

[46]  G. Bernardi,et al.  Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones , 2004, British journal of pharmacology.

[47]  Michael E Hasselmo,et al.  Blockade of central cholinergic receptors impairs new learning and increases proactive interference in a word paired-associate memory task. , 2004, Behavioral neuroscience.

[48]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[49]  C. Parsons,et al.  The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence , 2003, International journal of geriatric psychiatry.

[50]  J. Buccafusco,et al.  The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development , 2003, Journal of Pharmacology and Experimental Therapeutics.

[51]  E. Giacobini,et al.  Cholinergic function and Alzheimer's disease , 2003, International journal of geriatric psychiatry.

[52]  J. Kornhuber,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[53]  S. Hartmann,et al.  Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy , 2003, International clinical psychopharmacology.

[54]  J. Miguel-Hidalgo,et al.  Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40) , 2002, Brain Research.

[55]  R. Quirion,et al.  Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies , 2002, Progress in Neurobiology.

[56]  T. Oda,et al.  Glutamate exacerbates amyloid beta1-42-induced impairment of long-term potentiation in rat hippocampal slices. , 2002, Japanese journal of pharmacology.

[57]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[58]  Y. Koninck,et al.  Cholinergic nerve terminals establish classical synapses in the rat cerebral cortex: synaptic pattern and age-related atrophy , 2001, Neuroscience.

[59]  Kaj Blennow,et al.  Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease , 2001, Neuroscience Letters.

[60]  M. Sarter,et al.  Basal forebrain glutamatergic modulation of cortical acetylcholine release , 2001, Synapse.

[61]  Agneta Nordberg,et al.  Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implications , 2001, Biological Psychiatry.

[62]  W. Danysz,et al.  The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition , 2000, Experimental Brain Research.

[63]  C. Barnes,et al.  Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors , 2000, Neuroscience.

[64]  W. Danysz,et al.  No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. , 2000, Life sciences.

[65]  M. Weinstock,et al.  Selectivity of Cholinesterase Inhibition , 1999 .

[66]  C. Parsons,et al.  Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ In hippocampal slices , 1999, Neuropharmacology.

[67]  C. Parsons,et al.  Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.

[68]  H. Nakanishi,et al.  Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide , 1999, Neuroscience.

[69]  E. Perry,et al.  Acetylcholine in mind: a neurotransmitter correlate of consciousness? , 1999, Trends in Neurosciences.

[70]  R. Dingledine,et al.  The glutamate receptor ion channels. , 1999, Pharmacological reviews.

[71]  C. Parsons,et al.  Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization , 1999, Neuropharmacology.

[72]  B. Winblad,et al.  The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease , 1999, International journal of geriatric psychiatry.

[73]  C. Parsons,et al.  Glutamate in CNS disorders as a target for drug development: an update. , 1998, Drug news & perspectives.

[74]  C. Parsons,et al.  Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP , 1997, Neuropharmacology.

[75]  M. Weller,et al.  Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy , 1997, Biological Psychiatry.

[76]  B. Westerink,et al.  Septal and Hippocampal Glutamate Receptors Modulate the Output of Acetylcholine in Hippocampus: A Microdialysis Study , 1996, Journal of neurochemistry.

[77]  D. Butterfield,et al.  Amyloid β Peptide (25–35) Inhibits Na+‐Dependent Glutamate Uptake in Rat Hippocampal Astrocyte Cultures , 1996, Journal of neurochemistry.

[78]  C. Parsons,et al.  Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine. , 1996, European journal of pharmacology.

[79]  R. Anwyl,et al.  beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. , 1995, Neuroreport.

[80]  P. Francis,et al.  Cholinomimetics Increase Glutamate Outflow via an Action on the Corticostriatal Pathway: Implications for Alzheimer's Disease , 1995, Journal of neurochemistry.

[81]  S. L. Mobley,et al.  MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. , 1995, European journal of pharmacology.

[82]  K. Davis.  Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.

[83]  S. L. Mobley,et al.  Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat , 1994, Brain Research.

[84]  L. Bianchi,et al.  NMDA receptor antagonists decrease GABA outflow from the septum and increase acetylcholine outflow from the hippocampus: a microdialysis study , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[85]  C. Parsons,et al.  Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan) , 1993, Neuropharmacology.

[86]  Mark P. Mattson,et al.  β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease , 1993, Trends in Neurosciences.

[87]  J. Joseph,et al.  Changes in G Protein‐mediated Signal Transduction in Aging and Alzheimer's Disease , 1993, Annals of the New York Academy of Sciences.

[88]  N. Sims,et al.  Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives , 1993, Journal of neurochemistry.

[89]  S. Warach,et al.  Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[90]  G. Keilhoff,et al.  Memantine prevents quinolinic acid-induced hippocampal damage. , 1992, European journal of pharmacology.

[91]  R. Albin,et al.  Alternative excitotoxic hypotheses , 1992, Neurology.

[92]  J. Price,et al.  Sources of presumptive glutamatergic/aspartatergic afferents to the magnocellular basal forebrain in the rat , 1990, The Journal of comparative neurology.

[93]  S. Gershon,et al.  Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[94]  A. Young,et al.  Excitatory amino acids and Alzheimer's disease , 1989, Neurobiology of Aging.

[95]  D. Neary,et al.  Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. , 1985, The New England journal of medicine.

[96]  M M Mesulam,et al.  Neural inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey. , 1984, Brain : a journal of neurology.

[97]  D. Neary,et al.  Presynaptic Cholinergic Dysfunction in Patients with Dementia , 1983, Journal of neurochemistry.

[98]  Larry L. Butcher,et al.  Cholinergic projections from the basal forebrain to frontal, parietal, temporal, occipital, and cingulate cortices: A combined fluorescent tracer and acetylcholinesterase analysis , 1982, Brain Research Bulletin.

[99]  S. Mewaldt,et al.  The effects and interactions of scopolamine, physostigmine and methamphetamine on human memory , 1979, Pharmacology Biochemistry and Behavior.

[100]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[101]  D. Drachman,et al.  Memory and cognitive function in man , 1977, Neurology.

[102]  R. Petersen,et al.  Scopolamine induced learning failures in man , 1977, Psychopharmacology.

[103]  M. Riepe,et al.  Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[104]  C. Parsons,et al.  Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action , 2009, Neurotoxicity Research.

[105]  W. Klein,et al.  Molecules that Disrupt Memory Circuits in Alzheimer’s Disease: The Attack on Synapses by Aβ Oligomers (ADDLs) , 2007 .

[106]  Bruno Bontempi,et al.  Memories: molecules and circuits , 2007 .

[107]  A. Maelicke,et al.  The N-butylcarbamate derivative of galantamine acts as an allosteric potentiating ligand on alpha7 nicotinic receptors in hippocampal neurons: clinical implications for treatment of Alzheimer's disease. , 2006, Journal of molecular neuroscience : MN.

[108]  P. Francis,et al.  Cholinesterase Inhibitors Used in the Treatment of Alzheimer’s Disease , 2004, Drugs & aging.

[109]  R. Quirion,et al.  Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. , 2002, Progress in neurobiology.

[110]  M. Beal,et al.  Glutamate toxicity in chronic neurodegenerative disease. , 1998, Progress in brain research.

[111]  E. Giacobini,et al.  The cholinergic receptor system of the human brain: neurochemical and pharmacological aspects in aging and Alzheimer. , 1989, Progress in brain research.

[112]  D. Neary,et al.  Neurochemical studies of early-onset Alzheimerʼs disease , 1987 .